Unit 5: Ethical issues in Biotechnology

Bioethics is the systematic study of moral conduct in the life sciences, emerging as a formal discipline after the biomedical abuses of the mid-20th century (the Nuremberg Code, 1947; the Belmont Report, 1979). It provides the reasoning framework by which biotechnology's technical capabilities are weighed against human welfare, animal interests, and ecological limits. Later sections apply these foundations to society, research culture, medicine, and biodiversity.

Defining pillars of bioethics (the "four principles" of Beauchamp and Childress plus supporting norms):

• Autonomy: respect for a person's right to informed, voluntary decisions — operationalised as informed consent.
• Beneficence: the obligation to act for the benefit of others and maximise good outcomes.
• Non-maleficence: primum non nocere, "first, do no harm"; avoiding foreseeable injury.
• Justice: fair distribution of benefits, risks, and costs across individuals and groups.
• Supporting norms: dignity, privacy, confidentiality, and accountability, applied to humans, animals (the 3Rs: Replace, Reduce, Refine), and the environment.

II. Basics of Ethical Issues in Biology and Its Relation with Biotechnology and Other Branches

How moral questions arise in the life sciences and cross disciplinary boundaries.

Ethical issues in biology arise wherever living material is manipulated, owned, or altered, and biotechnology intensifies these by making manipulation deliberate and scalable.

A. Basics of ethical issues in biology and its relation with biotechnology and other branches

• Source of the issues: biology deals with living, sentient, and reproducing systems, so intervention carries consequences that non-living sciences do not — e.g. gene editing propagates through generations.
• Escalation by biotechnology: techniques such as recombinant DNA (rDNA), CRISPR-Cas9, cloning, and synthetic biology convert descriptive knowledge into the power to redesign organisms, raising questions of "should we" beyond "can we".
• Relation to other branches:
  • Law: patents, biosafety statutes, and liability define permissible action (e.g. Cartagena Protocol on Biosafety, 2000).
  • Philosophy and religion: frame views on the sanctity of life, the moral status of embryos, and "playing God".
  • Economics and policy: determine who funds, owns, and profits from innovations.
  • Ecology: assesses gene flow, invasiveness, and ecosystem disruption from released GMOs.
• Ethical frameworks applied:
  • Consequentialism: judges an act by its outcomes (net benefit vs harm).
  • Deontology: judges by adherence to duties and rights, regardless of outcome.

III. Application of Bioethics and Socioeconomic Impacts of Biotechnology

Translating principles into practice and tracing effects on society and economy.

Bioethics is not abstract; it is applied through committees, guidelines, and impact assessment, and its subject matter reshapes livelihoods and access.

A. Application of bioethics

• Institutional mechanisms: Institutional Ethics Committees (IEC) and Institutional Biosafety Committees (IBSC) review protocols before work begins; Data and Safety Monitoring Boards oversee trials.
• Informed consent: documented, comprehensible, voluntary agreement — the applied form of autonomy in clinical trials and genetic testing.
• Risk-benefit assessment: systematic weighing of probability and severity of harm against expected gain, required before GMO release or a first-in-human trial.
• Guidelines and codes: national frameworks (e.g. ICMR ethical guidelines, DBT recombinant DNA guidelines) convert principles into checklists.

B. Socioeconomic impacts of biotechnology

• Positive impacts:
  • Agriculture: Bt cotton and pest-resistant crops can raise yields and cut pesticide costs.
  • Health: recombinant insulin and vaccines lower production cost and improve supply.
  • Employment and industry: growth of biopharma and agri-biotech sectors.
• Negative and contested impacts:
  • Equity gap: costly patented seeds and therapies can favour large producers and wealthy patients, widening the rich-poor divide.
  • Farmer dependence: terminator (GURT) technology and seed-buyback obligations reduce autonomy.
  • Displacement: synthetic substitutes (e.g. lab-produced vanillin) can undercut smallholder crop economies.
  • Distributive justice: the "90/10 gap" — most R&D targets diseases of affluent markets rather than the global burden of disease.

IV. Public Education and Ethical Concerns of Biotechnology Research and Innovation

Building informed public participation and governing responsible research.

Because biotechnology affects everyone yet is understood by few, public understanding and research governance are themselves ethical obligations.

A. Public education

• Rationale: informed democratic consent requires scientific literacy; misinformation drives both undue fear and undue trust.
• Deficit vs dialogue models:
  1. Deficit model: treats the public as empty of knowledge, to be "filled" by experts — often ineffective and paternalistic.
  2. Dialogue/engagement model: two-way communication where public values shape research priorities — favoured for legitimacy.
• Channels: transparent labelling of GM foods, science communication, curricula, and public consultation before policy (e.g. debates preceding GM crop approvals).

B. Ethical concerns of biotechnology research and innovation

• Research integrity: honest data, avoidance of fabrication, falsification, and plagiarism; proper authorship and peer review.
• Dual-use dilemma: research that can be repurposed for harm — e.g. gain-of-function studies on pathogens increasing transmissibility.
• Biosafety and biosecurity: containment levels (BSL-1 to BSL-4) and controls against accidental release or deliberate misuse.
• Emerging-technology concerns:
  • Germline editing: heritable, irreversible changes and the risk of eugenics or "designer babies".
  • Synthetic biology: creation of novel organisms with uncertain ecological behaviour.
• Responsible Research and Innovation (RRI): anticipation, reflexivity, inclusion, and responsiveness built into the research cycle.

V. Bioethics in Health Care

Applying the four principles to genetics, reproduction, and clinical biotechnology.

Health care is where biotechnology touches individuals most directly, making autonomy, confidentiality, and justice acutely important.

A. Bioethics in health care

• Genetic testing and privacy:
  • Concern: predictive tests reveal risk (e.g. BRCA1/2 for breast cancer) affecting insurance and employment.
  • Safeguard: genetic non-discrimination protections and strict confidentiality; the "right not to know".
• Gene therapy:
  1. Somatic therapy: corrects non-heritable cells (e.g. treating SCID); ethically comparable to conventional treatment.
  2. Germline therapy: alters heritable DNA; widely restricted because consent of future generations is impossible.
• Reproductive technologies: IVF, preimplantation genetic diagnosis (PGD), and surrogacy raise questions of embryo status, sex selection, and commodification.
• Stem cells and cloning:
  • Therapeutic cloning: deriving stem cells for treatment — contested over embryo destruction.
  • Reproductive cloning: widely prohibited on grounds of safety and dignity.
• Justice in access: high-cost gene and cell therapies (e.g. CAR-T) strain equitable distribution; rationing decisions must be transparent.
• Clinical trial ethics: equitable subject selection, avoidance of exploiting vulnerable populations, and post-trial access to benefits.

VI. Bioethics in Biodiversity and Resource Management

Ethical stewardship of genetic resources, traditional knowledge, and ecosystems.

Biotechnology's raw material is biological diversity, so its use raises duties of fair sharing, conservation, and respect for indigenous communities.

A. Bioethics in biodiversity and resource management

• Ownership of genetic resources: the Convention on Biological Diversity (CBD, 1992) affirmed national sovereignty over genetic resources, ending "common heritage" free-for-all access.
• Access and Benefit Sharing (ABS): the Nagoya Protocol (2010) requires prior informed consent and equitable sharing of benefits with source communities.
• Biopiracy:
  • Definition: unauthorised commercial use or patenting of genetic resources or traditional knowledge without benefit sharing.
  • Illustrative cases: patent disputes over neem and turmeric, resolved by documenting prior knowledge (e.g. Traditional Knowledge Digital Library).
• Protecting traditional knowledge: recognising indigenous contributions as intellectual and moral property, not free inputs.
• GMOs and ecosystems:
  • Gene flow: transgenes escaping to wild relatives, creating "superweeds".
  • Non-target harm: effects on beneficial insects; loss of agrobiodiversity through monoculture.
• Conservation ethics:
  1. Anthropocentric view: nature valued for human use, justifying gene banks and bioprospecting.
  2. Ecocentric view: ecosystems and species hold intrinsic value independent of utility.
• Sustainable resource management: the precautionary principle — where serious or irreversible harm is possible, lack of full scientific certainty is not a reason to postpone protective measures.

B. Significance and integrating themes

• Precautionary principle as a bridge: links research governance (IV), health decisions (V), and environmental release (VI) under a shared caution toward irreversible harm.
• Justice as a recurring axis: distributive fairness reappears as access to therapies, seed affordability, and benefit sharing with communities.
• Governance layering: individual consent, institutional review, national law, and international protocol act together, so no single actor bears the ethical burden alone.